Whether 25 mM of metformin is achievable in human gut from a therapeutic dose of metformin?
Section snippets
Conflict of interest
The authors declare that they have no conflict of interest.
References (6)
“Metformin-resistant” folic acid producing probiotics or folic acid against metformin’s adverse effects like diarrhea
Med Hypotheses
(2017)- et al.
Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism
Cell
(2013) - et al.
Metformin and the gastrointestinal tract
Diabetologia
(2016)
There are more references available in the full text version of this article.
Cited by (3)
Metformin: A candidate drug to control the epidemic of diabetes and obesity by way of gut microbiome modification
2019, Microbiome and Metabolome in Diagnosis, Therapy, and other Strategic ApplicationsInhalational supplementation of metformin butyrate: A strategy for prevention and cure of various pulmonary disorders
2018, Biomedicine and PharmacotherapyCitation Excerpt :Pharmacokinetic studies in animals [6] and PET scans in humans suggest that metformin, even after absorption, concentrates in the intestines predominantly [148]. It has been recently suggested that mM concentrations of metformin are plausible in the intestinal lumen and that may explain some of the metformin’s actions [160]. The luminal concentrations of butyrate are in the mM range as well [10,11].
High dose targeted delivery on cancer sites and the importance of short-chain fatty acids for metformin's action: Two crucial aspects of the wonder drug
2018, Regulatory Toxicology and Pharmacology
© 2017 Elsevier Ltd. All rights reserved.